Previous Close | 372.81 |
1-Year Change | 61.87% |
6-Months Change | 57.35% |
3-Months Change | 13.26% |
Moving Avg (50d) | 349.25 |
Moving Avg (200d) | 282.41 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 17.5B |
Beta (3-Years) | 0.39 |
Revenue Growth (ttm) | 18.51% |
Net Profit Margin (ttm) | 40.69% |
Return On Assets (ttm) | 12.77% |
EPS (ttm) | 18.13 |
PE Ratio (ttm) | 20.56 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional... Wikipedia